Vaccine Geopolitics: Equity by 2027?

The world of vaccine manufacturing is being reshaped by two powerful forces: new technology and raw geopolitics. Aspiration for global vaccine access, especially after the last pandemic, is colliding with the hard realities of national interest, economic muscle, and strategic competition. This forces us to question how vaccines are made and distributed, and makes it clear that building a truly equitable system will be an uphill battle against these competing agendas.

The Uneven Distribution of Production Power

Don’t be fooled by talk of a “globalized” pharma industry, the real power in vaccine manufacturing capacity is incredibly lopsided. Sure, lots of countries can handle the final “fill and finish” steps, but the complex upstream work of producing active pharmaceutical ingredients (APIs) and other advanced components is locked down in a few places. Europe and North America, home to legacy pharma giants and mature regulatory bodies, are still in charge. A 2026 report from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) showed that facilities in those two regions, plus India and China, were still making over 70% of all vaccine doses.

That concentration is a huge vulnerability. When a crisis hits, countries with the factories naturally prioritize their own people. This “vaccine nationalism” defined the early 2020s and caused massive delays for lower-income countries. In those moments, the argument for domestic production as a national security issue becomes impossible to ignore, but it makes global inequality much worse. For example, despite a lot of talk about tech transfer, getting new manufacturing sites operational in Africa has been sluggish due to serious regulatory hurdles, infrastructure problems, and a shortage of trained people. The African Union’s goal to produce 60% of the continent’s own vaccines by 2040, outlined in their Pharmaceutical Manufacturing Plan for Africa, is a great ambition, but it’s going to need serious, sustained international backing to happen.

Geopolitical Strategies and Supply Chain Resilience

Geopolitics is now a primary driver of vaccine supply chain strategy. Governments aren’t just watching from the sidelines anymore. They’re on the field, using diplomatic use, trade deals, and export controls to get what they need. The United States, for instance, has poured money into its own biomanufacturing through programs like the Biomedical Advanced Research and Development Authority (BARDA) specifically to stop relying on foreign supply chains for key medicines. It makes sense from a national security point of view, but it also risks breaking up the global market. At the same time, China’s “Health Silk Road” initiative is expanding its pharma influence in Asia and Africa, bundling vaccine donations with infrastructure projects and political goodwill. This isn’t altruism. It’s a play to extend soft power and lock in long-term economic relationships.

Countries are responding to this new reality by trying to build their own regional manufacturing hubs. Nations in Southeast Asia, Latin America, and Africa are all working on strategies to build out their vaccine production capabilities. Just look at Brazil, which has a solid history of local production through institutions like Fiocruz and the Butantan Institute that have been absolutely essential for its own immunization programs and for exports across the region. The problem is that these efforts run into big walls, including getting access to proprietary tech, finding stable sources of raw materials (which often come from the same few powerful countries), and hiring people who know what they’re doing. Building a truly resilient and diversified global supply chain requires far more than pouring concrete for new facilities. It means changing the entire game of how IP is managed and technology is shared, shifting from short-term deals to real, sustained partnerships.

The Intellectual Property Debate and Technology Transfer

The fight over intellectual property (IP) rights for vaccines remains one of the most heated geopolitical battlegrounds. At the peak of the pandemic, there was a huge international push from developing nations to waive IP protections for COVID-19 vaccines. They argued that patents were a barrier to public health and that a waiver would speed up production everywhere. On the other side, pharma companies and their home governments argued that IP is what fuels innovation and that forcing them to share it would kill the incentive for future R&D. The World Trade Organization (WTO) eventually brokered a narrow agreement in 2022 for a temporary waiver on some COVID-19 vaccine IP, but the argument over what to do in the *next* pandemic is far from over.

I think the current IP framework, while it does drive innovation, has to be balanced with mechanisms that guarantee rapid global access when there’s a public health emergency. The answer isn’t just blanket waivers. We need to be exploring models like patent pools, tiered pricing, and proactive technology transfer agreements that are baked into our pandemic plans from day one. The development of mRNA vaccines is a perfect opportunity here. The manufacturing is simpler compared to older vaccine types which means it can be set up in more places with the right training and equipment. The establishment of mRNA tech transfer hubs, like the one in South Africa backed by the World Health Organization (WHO), is a concrete step toward decentralizing vaccine production and letting regions build their own next-gen vaccines.

The Rise of Biosecurity and Dual-Use Technologies

Vaccine manufacturing has moved beyond public health and is now firmly a part of national biosecurity strategy. The ability to quickly cook up a vaccine for a new bug is now seen as a core strategic asset. This view has prompted huge government investments in biomanufacturing infrastructure for both pandemic response and potential biodefense. It also introduces the tricky subject of dual-use technologies (tech with both civilian and military uses). The worry is that the same advanced bioreactors or gene sequencers used for legitimate vaccine production could, in theory, be repurposed for developing biological weapons, even with heavy regulation and monitoring.

This focus on biosecurity creates a weird tension. On one hand, it encourages countries to work together on things like pathogen surveillance and building rapid-response platforms. On the other, it leads them to guard their technology and slap export controls on critical equipment to protect their strategic edge. It’s a delicate balance. Every nation needs to protect its people, but an overly protectionist approach to biomanufacturing actually hurts global health security by shrinking the world’s total capacity to fight a widespread threat. International groups like the WHO and various G7/G20 initiatives have to set clear rules and promote transparency around these capabilities to stop the field from becoming dangerously fragmented.

Future Outlook: Towards a More Distributed Model?

The future of vaccine manufacturing looks more distributed, but geopolitics will still be pulling the strings. The hard lessons from the last global health crisis proved that highly centralized supply chains are just too fragile. The big pharma hubs will still be important, but the pressure will continue to build regional manufacturing, especially in places that have always had to import their doses. This isn’t just about fairness. It’s about building a more resilient global health system with redundancy baked in from the start. It means developing local scientific talent, building strong regulatory agencies, and finding consistent funding for R&D in these new hubs.

In the next decade, expect to see a lot more public-private partnerships trying to scale up regional production while also trying to simplify the nightmare of cross-border regulatory approvals. But all of this will happen against a backdrop of competing national interests. The real work is figuring out how to align these different agendas to create a global vaccine system that can actually respond to medical need, not just to a country’s bank account or political alliances.

We have to strategically shift to a network of diversified, resilient regional hubs. It’s the only way to reduce geopolitical vulnerabilities and guarantee faster, fairer access in the next crisis. For a broader view of health-related economic indicators, consider insights on how disease is an economic indicator.